EL7.AI
StocksMediumUpdated•Originally published 9 March 2026•Updated 9 March 2026•
1 min read

ImmunityBio Shares Trade Lower Despite Resubmission of ANKTIVA Application to FDA

Key Facts

1ImmunityBio announced the resubmission of a supplemental Biologics License Application (sBLA) for ANKTIVA plus BCG for the treatment of papillary NMIBC.
2The FDA acknowledged receipt of the filing following a review of additional data provided by the company in February 2026.
3The treatment targets approximately 70% of NMIBC patients who present with papillary disease.

ImmunityBio (NASDAQ: IBRX) shares traded lower on Monday despite the company officially resubmitting its supplemental Biologics License Application (sBLA) to the U.S. FDA for its immunotherapy ANKTIVA. The application seeks approval for ANKTIVA in combination with the BCG vaccine to treat patients with papillary non-muscle invasive bladder cancer (NMIBC). The FDA acknowledged receipt of the filing following a comprehensive review of additional data submitted by the company in February 2026. This specific treatment targets approximately 70% of NMIBC patients, addressing a significant unmet medical need in the oncology sector. While the regulatory milestone is a positive step toward expanding market reach, the immediate market reaction saw the stock price retreat. Investors remain focused on the FDA's final decision, as approval would be a major catalyst for the company's growth strategy.